… non-small cell lung cancer (NSCLC) and extended-RAS for colorectal … of advanced NSCLC
patients treated in the community setting identified gaps in national guideline based genomic …

… genomic profiling [CGP]) and non-NGS-based genomic testing … therapy options (<4 genes
tested with no positive results). … , reflecting the community oncology care setting in the US. …

… outcomes based on plasma-based comprehensive genomic profiling are comparable to
published targeted therapy outcomes with tissue profiling, even in community-based centers. …

… therapies in lung cancer, to report the gaps in community practice … with cancer are treated
in the community setting and 50% of collaborative group trial accruals occur in the community […

… , the introduction of comprehensive genomic profiling (CGP) in … genomic profiling in NSCLC.
The results have shown the utility and potential benefit of comprehensive genomic profiling, …

… testing program for NSCLC in a community-based health care setting that may be of utility
to … our diverse health system are most affected by gaps in access to testing and or precision …

… gaps associated with diagnostic testing-informed personalized medicine strategies on the
treatment of advanced non–small-cell lung cancer … checkpoint inhibitors from genetic testing to …

… of molecularly defined somatic genomic alterations or driver … , particularly in the community
setting. In a retrospective chart … effort to evaluate any remaining gaps in care for future study. …

… and community settings. The claims data are provided by a commercial agreement with a
data aggregator (the ‘parent dataset’), which collates high-quality industry-standard sources of …

… and 12-month survival in NSCLC in community oncology settingsCitation 40 , there were
notable gaps between the identification of alterations and use of treatments informed by those …